Dr. Reddys Laboratories Ltd.
BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1273.90
-1.15 (-0.09%) Dr. Reddy’s Laboratories informs about media release
Date: 21-03-2026Dr. Reddy’s Laboratories has informed that it enclosed a Press Release titled “Dr. Reddy’s Laboratories announces launch of India’s first DCGI-approved Semaglutide injection ‘Obeda®’ for Type 2 Diabetes.’
The above information is a part of company’s filings submitted to BSE.